Deep brain stimulation in the bed nucleus of the stria terminalis and medial forebrain bundle in a patient with major depressive disorder and anorexia nervosa

Patric Blomstedt1, Matilda Naesström2 & Owe Bodlund2

1Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden  
2Department of Clinical Sciences/Psychiatry, Umeå University, Umeå, Sweden

Correspondence  
Patric Blomstedt, Department of Clinical Neurosciences, University Hospital of Umeå, SE-901 85, Umeå, Sweden.  
Tel: +46907850000; Fax: +4690138045;  
E-mail: patric.blomstedt@neuro.umu.se

Funding Information  
No sources of funding were declared for this study.

Introduction  
In deep brain stimulation (DBS), thin quadripolar electrodes connected to a neuropacemaker are implanted into subcortical central structures of the brain where pathological neuronal activity is modulated with electrical current [1]. The method has revolutionized the treatment of Parkinson’s disease and other movement disorders and is under investigation for, among others, some psychiatric conditions [2]. In this group, DBS has shown some promising results, but the case material is limited and heterogeneous, consisting mainly of small nonrandomized studies with electrodes implanted in many different brain target structures [3]. Here, we present a patient with severe major depressive disorder (MDD) and comorbid anorexia nervosa treated with DBS in the medial forebrain bundle (MFB) and subsequently in the bed nucleus of the stria terminalis (BNST). The MFB is typically regarded as a reward-based pathway, and it is believed that dopaminergic neurotransmission plays an important role in MFB stimulation [4]. The BNST serves as a major output pathway of the amygdala and has a complex role in regulating threat monitoring and anxiety. Dysfunction in this nucleus is believed to have an important role in anxiety disorders, partly through serotonergic activity [5].

Case Presentation  
History  
The patient, a 60-year-old woman, had a childhood onset of anxiety and anorexia nervosa, with symptoms of anxiety connected to food intake, restricted eating, and, later on, purging. The course of the eating disorder was remitting and relapsing with episodes at age 14, 28, and, most recently, age 44. The last episode had a prolonged course and, over time her, depressive symptoms became more and more severe, and since the age of 47, her main problem was MDD, with significant symptoms of anxiety. By the end, her eating disorder had clear depressive components with thoughts of being a burden on relatives, of eating being worthless and having suicidal ideations about starving to death. At the age of 54, the patient was committed to a closed psychiatric ward.
Treatment

The patient had tried and failed psychotherapy, including several different classes of antidepressant, for example, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, mood stabilizers, neuroleptics, ketamine infusions, and transcranial magnetic stimulation with little or no effect (details of medication trials are presented in detail in Table 1). The only treatment providing relief was electroconvulsive therapy (ECT), and since many years ago, she had had three sessions of ECT every 4 weeks. Unfortunately, ECT resulted in a gradual loss of memory, finally removing most of her memories from before her 30th year of age. Attempts to reduce the frequency of ECT sessions failed as this resulted in several suicide attempts while being treated.

Therefore, after extensive screening and obtaining her informed consent, the patient was included in an ongoing study of DBS for major depressive disorder (MDD). The MFB was chosen as the target based on a recent report, which highlighted the acute and quick effect of this treatment [6].

When she was evaluated before surgery at baseline, the patient weighted 40 kg with a body mass index (BMI) of 16.6. She was deemed to be severely depressed. She scored 43 points on the Montgomery–Asberg Depression Rating Scale (MADRS), 22 on the Hamilton Rating Scale for Depression (HAM-D), and 34 on the Hamilton Rating Scale for Anxiety (HAM-A). She preferred lying alone in a dark room. She exhibited reduced facial mimicry. She responded adequately to questions, but with short sentences and a monotonous voice.

At age 56, the patient underwent implantation of two DBS electrodes (Medtronic model 3389) in the area of the MFB in the posterior hypothalamic area, just anterior to the red nucleus (Fig. 1). Stimulation was initiated 2 days after surgery. When the patient returned 1 week later, the effect was perceived as being dramatic. She considered herself to be “quite happy.” She had a normal facial mimicry, spoke fluently, and smiled occasionally.

Bipolar stimulation was delivered using three contacts on each side, at 130 Hz and 60 μsec. The voltage was gradually increased and after 4 months was 2.8 V on the left side and 3.0 V on the right. A further increase was not possible as it caused blurred vision. At 6 months, MADRS was reduced to 26 points, HAM-D 22 and HAM-A to 21 (results are presented in detail in Table 2).

Ten months after the procedure, the patient complained of blurred vision. Numerous adjustments of stimulation and the cessation of lamotrigine (given the possibility of the drug being able to attenuate visual side effects) were tried in the following period without success [7]. The symptom was partly stimulation induced, but even after the stimulation had been turned off for 2 weeks, some minor symptoms remained. The stimulation was restarted with a voltage reduced to a level where the side effects were tolerable, however, with a reduced effect on her psychiatric symptoms.

Two years after the first procedure, the patient was therefore re-operated upon, with implantation of bilateral electrodes (Medtronic model 3387) in the BNST (Fig. 1). The patient received monopolar stimulation through two contacts on each electrode with a gradually increasing voltage. At 12 months, the patient received 130 Hz, 120 μsec and 4.3 V bilaterally. The stimulation in the MFB was reduced and turned off simultaneously without any signs of deterioration.

Outcome and follow-up

The improvement seen after BNST DBS was more gradual, but very profound. Nine months after surgery, the patient was released from the psychiatric ward and returned to her home. Prior to this, she had been subject to hospital care, initially, due to her eating disorder and lastly due to severe MDD with suicidal ideation, for almost 4 years. She is now living full time at home with her family and is participating in social gatherings and outdoor activities. She considers herself to be profoundly improved, and at 12 months, her MADRS was reduced to 13 points, with an HAM-D score of six and an HAM-A of 5 points.

Throughout the postoperative periods, neither of the surgical procedures had any significant effect on her anorexia, in terms of BMI. However, following the second procedure, all her anxiety concerning food and eating vanished. She has virtually

Table 1. Previous medications administered with dosing regimens and length of medication trials.

| Medication      | Dosage regime | Duration |
|-----------------|---------------|----------|
| Phenelzine      | 15 mg 2 + 1 + 1 | 6 weeks  |
| Valproate       | 500 mg 1 + 0 + 1 | 4 weeks  |
| Lithium         | 42 mg 1 + 0 + 1 | 102 weeks|
| Pregabalin      | 150 mg 1 + 0 + 1 | 39 weeks |
| Perphenazine    | 2 mg 0 + 0 + 1  | 84 weeks |
| Olanzapine      | 2.5 mg 1 + 0 + 0 | 30 weeks |
| Clomipramine    | 75 mg 0 + 0 + 2 | 153 weeks|
| Escitalopram    | 20 mg 1 + 0 + 0 | 78 weeks |
| moclobemide     | 300 mg 1 + 0 + 1 | 20 weeks |
| Bupropion       | 150 mg 1 + 0 + 0 | 5 weeks  |
| Duloxetine      | 60 mg 0 + 1 + 0  | 32 weeks |
| Sertraline      | 50 mg 1 + 0 + 0  | 4 weeks  |
| Mirtazapine     | 15 mg          | Discontinued due to drug-induced granulocytopenia |
stopped vomiting, her food intake is more stable and less prone
to large variations, and tube feeding could be discontinued.
However, in the words of the patient, she continues, out of
habit to eat just enough to keep her weight stable, even in the
absence of anxiety or obsessive thoughts. She is now, however,
motivated to start behavioral training to change this pattern.

Discussion
According to WHO, depression is one of the most com-
mon cause of disability with a prevalence of 3–5% and
the STAR*D studies have demonstrated the limitations of
conventional treatments [8–10]. Not only is depression

Table 2. Evaluations before and 6, 12 and 24 months after first surgery, and 6 and 12 months after second surgery.

|                  | Baseline pre-op | 6 months | 12 month | 24 months/Baseline second surgery | (30 months) | (36 months) |
|------------------|-----------------|----------|----------|----------------------------------|-------------|-------------|
| MADRS            | 43              | 26       | 33       | 27                               | 14          | 13          |
| HAM-D            | 22              | 22       | 30       | 15                               | 15          | 6           |
| HAM-A            | 34              | 21       | 24       | 27                               | 10          | 15          |
| GAF              | 30              | 45       | 52       | 55                               | 60          | 65          |
| BMI              | 16.2            | 16.2     | 16.5     | 15.2                             | 14.5        | 14.3        |
| NRS-11 Depression| NA              | 7        | 8        | 8                                | 1           | 0           |
| Anxiety          | NA              | 4        | 5        | 3                                | 1           | 0           |
| Obsessions       | NA              | 8        | 6        | 1                                | 0           | 0           |
| Compulsions      | NA              | 1        | 2        | 1                                | 0           | 0           |

MADRS, Montgomery–Asberg Depression Rating Scale; HAM-D, Hamilton Rating Scale for Depression; HAM-A, Hamilton Rating Scale for Anxiety; GAF, global assessment of function; BMI, body mass index; NRS-11, numeric rating scale 0–10; NA, not available.
associated with the suffering of the patients, an often severe social handicap and a reduced quality of life, but also with a significant mortality. It is estimated that 90% of the suicides are related to psychiatric diseases, the most common cause being depression, where the mortality due to suicide is around 10–15% [11]. The frequency of therapy-resistant MDD is estimated to range from 12% to –30% [12, 13].

Anorexia nervosa has one of the highest mortality rates of any psychiatric disorder, and the presence of anxiety and mood disturbances portends a worse prognosis of the disorder [14]. As for depression, conventional treatment methods have demonstrated limitations. Pharmacological methods have been shown to be ineffective in anorexia nervosa [15]. Even with psychotherapy and self-help programs, with an effectiveness of around 50%, there remains a group of patients with intractable symptoms [16].

Even though the majority of patients will respond well to noninterventional therapy, there remains a significant group in both depression and anorexia nervosa, in whom conventional treatment will yield little or no relief of symptoms. In severely affected patients in whom therapy-resistant symptoms have caused a high degree of suffering and handicap, interventional procedures in the form of stereotactic functional neurosurgery might be indicated.

The experience of DBS in MDD is still limited. A total of 100 patients treated with DBS for MDD in nine different studies and involving several brain targets have been published [17]. The most common targets are the subcallosal cingulate gyrus (SCCG), the nucleus accumbens (NA), and the ventral caudate/ventral striatum (VC/VS) [18–20]. The inferior thalamic peduncle and the lateral habenula were the target in two case reports [21, 22]. The most recently published brain target for DBS in depression is the MFB, where results have been presented for seven patients [6]. The results of DBS for depression have generally been promising, although recent blinded randomized multicenter studies in the USA have failed to demonstrate a benefit of active stimulation compared to sham stimulation [19]. Regarding the BNST, reports on this target have only been published in one study on DBS for obsessive compulsive disorder (OCD), but not on MDD [23].

In our patient, the MFB, connecting the amygdala, ventral tegmental area, the NA, ventromedial, and the lateral nuclei of the hypothalamus, was initially chosen as the target as the onset of effect has been reported to be rapid [6]. A fast onset of effect was deemed to be essential considering the patient’s dependency on ECT and the fact that it may not be possible to administer ECT after DBS. Blurred vision following this procedure was described in the original publication [6], even though not in the manner described here with a late appearance and semireversibility.

When a second surgery was considered to be indicated, the BNST, a part of the anxiety-regulating network between the amygdala, hypothalamus, thalamus, and the orbitofrontal cortex [23], was chosen as the target. This decision was based on our own experience of the effect of BNST DBS for concomitant depressive symptoms and anxiety in patients with OCD and generalized anxiety disorder (GAD) [unpublished data]. Furthermore, studies have pointed out the BNST as an important brain structure involved in anorexia nervosa and anxiety disorders [23–26].

Even though the indication for this procedure was MDD, it would not have been unreasonable to expect a positive effect on the patient’s concomitant anorexia. The effects of improved mood and anxiety could potentially disrupt important illness-maintaining factors. The improvement in this patient’s mood, anxiety, and quality of life, despite the remaining sign of underweight, is promising, in view of the well known poor response of underweight patients to conventional pharmacological and psychological therapies. In the literature published in five reports, DBS for anorexia has been performed on three different brain targets in 14 patients, several with concomitant MDD, OCD, or GAD. The SCCG was targeted in seven patients [27, 28], NA in six [29, 30], and the VC/VS in one [31]. Most patients in this heterogeneous material seem to have benefited to various extents from the procedures.

Conclusion

Even though DBS might offer hope to patients with severe treatment-resistant MDD, it is important to stress that DBS for MDD is a still an experimental therapy. Therefore, prior to labeling a case of MDD as “treatment-resistant,” it is essential to ensure that adequate trials of treatment methods have been conducted. There is currently no consensus on the definition of treatment-resistant MDD, and clinical trials differ in inclusion criteria [32]. Prior to considering referral for such experimental therapies as DBS for MDD, we suggest that practicing clinicians should follow local guidelines for MDD treatment, including considering the use of more aggressive antidepressant treatments, such as ECT and MAOIs.

Authorship

PB and MN: conducted the acquisition of information for the case and drafted the initial version of the manuscript. OB: critically edited and revised the initial draft of the manuscript with regard to important intellectual
content, with a focus on the psychiatric aspects. All authors discussed the case and commented on the manuscript at all stages and gave their final approval of the version to be published in Clinical Case Reports.

**Conflict of Interest**

PB: is a consultant for Medtronic and a shareholder in Mithridaticum AB. MN: has no disclosure or conflict of interest to declare. OB: has no disclosure or conflict of interest to declare.

**References**

1. Herrington, T. M., J. J. Cheng, and E. N. Eskandar. 2016. Mechanisms of deep brain stimulation. J. Neurophysiol. 115:19–38.
2. Hariz, M., P. Blomstedt, and L. Zrinzo. 2013. Future of brain stimulation: new targets, new indications, new technology. Mov. Disord. 28:1784–1792.
3. Krack, P., M. I. Hariz, C. Baunez, J. G. Guridi, and J. A. Obeso. 2010. Deep brain stimulation: from neurology to psychiatry? Trends Neurosci. 33:474–484.
4. Hernandez, G., S. Hamdani, H. Rajabi, K. Conover, J. Stewart, A. Arvanitogiannis, et al. 2006. Prolonged rewarding stimulation of the rat medial forebrain bundle: neurochemical and behavioral consequences. Behav. Neurosci. 120:888–904.
5. Lebow, M. A., and A. Chen. 2016. Overshadowed by the amygdala: the bed nucleus of the stria terminalis emerges as key to psychiatric disorders. Mol. Psychiatry 21:450–463.
6. Schlaepfer, T. E., B. H. Bewernick, S. Kayser, B. Madler, and V. A. Coenen. 2010. Rapid effects of deep brain stimulation for treatment-resistant major depression. Biol. Psychiatry 73:1204–1212.
7. Han, H., W. Qu, H. Kang, X. Hu, G. Zhen, S. Zhu, et al. 2012. Effect of second-generation antiepileptic drugs on diplopia: a meta-analysis of placebo-controlled studies. J. Huazhong Univ. Sci. Technolog. Med. Sci. 32:557–562.
8. Giacobbe, P., H. S. Mayberg, and A. M. Lozano. 2009. Treatment resistant depression as a failure of brain homeostatic mechanisms: implications for deep brain stimulation. Exp. Neurol. 219:44–52.
9. Ferraro, J. F., J. Charlson, R. E. Norman, S. B. Patten, G. Freedman, C. J. Murray, et al. 2013. Burden of depressive disorder by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 10:e1001547.
10. World Health Organization (WHO). 2004. The global burden of disease: 2004 update.
11. Robertson, M. M. 2006. Mood disorders and Gilles de la Tourette’s syndrome: an update on prevalence, etiology, comorbidity, clinical associations, and implications. J. Psychosom. Res. 61:349–358.
12. Mrazek, D. A., J. C. Hornberger, C. A. Altar, and I. Degtiar. 2014. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr. Serv. 65:977–987.
13. Rush, A. J., M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart, D. Warden, et al. 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163:1905–1917.
14. Berkman, N. D., K. N. Lohr, and C. M. Bulik. 2007. Outcomes of eating disorders: a systematic review of the literature. Int. J. Eat. Disord. 40:293–309.
15. Tamburrino, M. B., and R. A. McGinnis. 2002. Anorexia nervosa. A review. Panminerva Med. 44:301–311.
16. Zipfel, S., B. Lowe, D. L. Reas, H. C. Deter, and W. Herzog. 2000. Long-term prognosis in anorexia nervosa: lessons from a 21-year follow-up study. Lancet 355:721–722.
17. Naesstrom, M., P. Blomstedt, and O. Bodlund. 2016. A systematic review of psychiatric indications for deep brain stimulation, with focus on major depressive and obsessive-compulsive disorder. Nord. J. Psychiatry 70:483–91.
18. Malone, D. A. Jr, D. D. Dougherty, A. R. Rezai, L. L. Carpenter, G. M. Friehs, E. N. Eskandar, et al. 2009. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol. Psychiatry 65:267–275.
19. Dougherty, D. D., A. R. Rezai, L. L. Carpenter, R. H. Howland, M. T. Bhati, J. P. O’Reardon, et al. 2015. A randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. Biol. Psychiatry 78:240–248.
20. Bewernick, B. H., R. Hurlemann, A. Matusch, S. Kayser, C. Grubert, B. Hadrysiewicz, et al. 2010. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol. Psychiatry 67:110–116.
21. Sartorius, A., K. L. Kiening, P. Kirsch, C. C. van Gall, U. Haberkorn, A. W. Unterberg, et al. 2010. Remission of major depression under deep brain stimulation of the lateral habenula in a therapy-refractory patient. Biol Psychiatry 78:240–248.
22. Jimenez, F., F. Velasco, R. Salin-Pascual, J. A. Hernandez, M. Velasco, J. L. Ciales, et al. 2005. A patient with a resistant major depression disorder treated with deep brain stimulation in the inferior thalamic peduncle. Neurosurgery 57:585–593. discussion -93.
23. Luyten, L., S. Hendrickx, S. Raymaekers, L. Gabriels, and B. Nuttin. 2015. Electrical stimulation in the bed nucleus of the stria terminalis alleviates severe obsessive-compulsive disorder. Mol. Psychiatry 21:1272–80.
24. Cicciocipppo, R., M. Biondini, L. Antonelli, J. Wichmann, F. Jenck, and M. Massi. 2002. Reversal of stress- and CRF-
induced anorexia in rats by the synthetic nociceptin/orphanin FQ receptor agonist, Ro 64-6198.
Psychopharmacology 161:113–119.
25. Ciccocioppo, R., A. Fedeli, D. Economidou, F. Policani, F. Weiss, and M. Massi. 2003. The bed nucleus is a neuroanatomical substrate for the anorectic effect of corticotropin-releasing factor and for its reversal by nociceptin/orphanin FQ. J. Neurosci. 23:9445–9451.
26. Luyten, L., C. Casteels, D. Vansteenwegen, K. van Kuyck, M. Koole, K. Van Laere, et al. 2012. Micro-positrion emission tomography imaging of rat brain metabolism during expression of contextual conditioning. J. Neurosci. 32:254–263.
27. Lipsman, N., D. B. Woodside, P. Giacobbe, C. Hamani, J. C. Carter, S. J. Norwood, et al. 2013. Subcallosal cingulate deep brain stimulation for treatment-refractory anorexia nervosa: a phase 1 pilot trial. Lancet 381:1361–1370.
28. Israel, M., H. Steiger, T. Kolivakis, L. McGregor, and A. F. Sadikot. 2010. Deep brain stimulation in the subgenual cingulate cortex for an intractable eating disorder. Biol. Psychiatry 67:e53–e54.
29. Wu, H., P. J. Van Dyck-Lippens, R. Santegoeds, K. van Kuyck, L. Gabriels, G. Lin, et al. 2013. Deep-brain stimulation for anorexia nervosa. World Neurosurg. 80: S29. e1–e10.
30. Wang, J., C. Chang, N. Geng, X. Wang, and G. Gao. 2013. Treatment of intractable anorexia nervosa with inactivation of the nucleus accumbens using stereotactic surgery. Stereotact. Funct. Neurosurg. 91:364–372.
31. McLaughlin, N. C., E. R. Didie, A. G. Machado, S. N. Haber, E. N. Eskandar, and B. D. Greenberg. 2013. Improvements in anorexia symptoms after deep brain stimulation for intractable obsessive-compulsive disorder. Biol. Psychiatry 73:e29–e31.
32. Berlim, M. T., and G. Turecki. 2007. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur. Neuropsychopharmacol. 17:696–707.